Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GDX012 |
| Synonyms | |
| Therapy Description |
GDX012 is an allogeneic cell therapy comprising gamma delta T-lymphocytes, which potentially induce cytotoxicity in tumor cells (Cancer Res (2022) 82 (12_Supplement): CT525). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GDX012 | GDX 012|GDX-012 | GDX012 is an allogeneic cell therapy comprising gamma delta T-lymphocytes, which potentially induce cytotoxicity in tumor cells (Cancer Res (2022) 82 (12_Supplement): CT525). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05886491 | Phase Ib/II | Cyclophosphamide + Fludarabine GDX012 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |